Salvage Therapy With Selpercatinib for RET-Rearranged NSCLC With Pralsetinib-Related Pneumonitis and Leptomeningeal Disease: A Case Report

Salvage Therapy With Selpercatinib for RET-Rearranged NSCLC With Pralsetinib-Related Pneumonitis and Leptomeningeal Disease: A Case Report

Selpercatinib and pralsetinib are RET inhibitors with substantial activity in advanced RET-rearranged NSCLC. We present a case of pralsetinib-related pneumonitis and leptomeningeal and brain metastases progression during treatment suspension for pneumonitis. During recovery, selpercatinib administra...

Full description

Bibliographic Details
Main Authors: Paolo D. d'Arienzo, MD, MRCP, Niamh Cunningham, MBBS, BSc, MRCP, Hazel O’Sullivan, MBBchBAO, MRCPI, Charlotte Grieco, MBBS, MRCP, Virjen Patel, MbChB, BSc, FRCR, Sanjay Popat, PhD, FRCP
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:JTO Clinical and Research Reports
Subjects:
Selpercatinib
Pralsetinib
RET fusion
Leptomeningeal disease
NSCLC
Case Report
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364323001248

Internet

http://www.sciencedirect.com/science/article/pii/S2666364323001248

Similar Items